Outsourcing's, Race Toward Novelty
Pharmaceutical Technology Europe
; 34(1):32-33, 2022.
Article
in English
| ProQuest Central | ID: covidwho-20241369
ABSTRACT
According to Jeetendra Vaghjiani, senior director of clinical development and strategic marketing at Lonza, emerging biotech companies are reliant on contract development and manufacturing organizations (CDMOs) because of their development and manufacturing capacity, expertise, and flexibility. Because of the high attrition rate associated with drug development, the better your preclinical programme, the stronger the position you can establish in terms of programme design and patient identification (2). [...]because of the relative scarcity of approvals over the past decade, companies looking to capitalize on this new market are likely to require specialized knowledge to get through the approvals process.
Search on Google
Collection:
Databases of international organizations
Database:
ProQuest Central
Type of study:
Prognostic study
Language:
English
Journal:
Pharmaceutical Technology Europe
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS